Clinical Performance of a Dermal Filler Containing Natural Glycolic Acid and a Polylactic Acid Polymer

Tagle, Jorge M.; Macchetto, Pedro Cervantes; Páramo, Rosa Margarita Durán
February 2010
Journal of Clinical & Aesthetic Dermatology;Feb2010, Vol. 3 Issue 2, p42
Academic Journal
Lipoatrophy is a condition that affects certain individuals, most commonly those who are infected with the human immunodeficiency virus. Injectable fillers are used for the treatment of these dermal contour deformities to smooth dermal depressions formed by the loss of volume. These dermal fillers (also known as soft tissue augmentation devices) can correct contour deformities caused by lipoatrophy in patients who are human immunodeficiency virus positive or negative. The product used in this study is a patented, second-generation, injectable, dermal collagen stimulator that combines glycolic acid and polylactic acid. The glycolic acid used is not a polymer, but rather an acid derived from sugar cane. Its chemical structure corresponds to that of an alpha-hydroxy acid. Glycolic acid is a well-characterized agent that is present in a number of cosmetic products. Polylactic acid is a synthetic, biocompatible, biodegradable, inert, synthetic polymer from the poly a-hydroxy-acid family that is believed to stimulate fibroblasts to produce more collagen, thus increasing facial volume. Together, polylactic acid and glycolic acid act in concert to 1) stimulate collagen production and 2) hydrate the outer layers of the skin. A multicenter, clinical investigation authorized by the Mexican Secretariat of Health was conducted between September 20, 2002, and September 19, 2004. This clinical study was conducted in male patients between 32 and 60 years of age with lipoatrophy as a result of highly active antiretroviral therapy for human immunodeficiency virus infection. The study objective was to measure the improvement of contour deformities after the injection of a dermal collagen stimulator containing glycolic acid and polylactic acid. In addition to safety, this dermal filler was assessed when used to correct volume deformities caused by lipoatrophy in subjects who are human immunodeficiency virus positive. Thirty male subjects participated and were treated as follows: seven in two sessions, eight in three sessions, 14 in four sessions, and one in five sessions. Each treatment session was separated by approximately 20 days as per the manufacturer's instructions. The follow-up phase consisted of four observation periods over two years from the last injection. The primary efficacy endpoint was measurement of correction of human immunodeficiency virus highly active antiretroviral therapy induced facial lipoatrophy. Using a multipoint scale of facial divergence, correction was measured as a percentage of correction (diversion correction percentage) from baseline.…


Related Articles

  • Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure. Paredes, Roger; Lalama, Christina M.; Ribaudo, Heather J.; Schackman, Bruce R.; Shikuma, Cecilia; Giguel, Francoise; Meyer III, William A.; Johnson, Victoria A.; Fiscus, Susan A.; D'Aquila, Richard T.; Gulick, Roy M.; Kuritzkes, Daniel R. // Journal of Infectious Diseases;3/1/2010, Vol. 201 Issue 5, p662 

    Background. The clinical relevance of detecting minority drug-resistant human immunodeficiency virus type 1 (HIV-1) variants is uncertain. Methods. To determine the effect of pre-existing minority nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant variants on the risk of virologic...

  • High Frequency of Advanced Hepatic Disease among HIV/HCV Co-Infected Patients in Cambodia: The HEPACAM Study (ANRS 12267). Lerolle, Nathalie; Limsreng, Setha; Fournier-Nicolle, Isabelle; Sowath Ly; Nouhin, Janin; Guillard, Bertrand; Ken, Sreymom; Dulioust, Anne; Pichit Khuon; Delfraissy, Jean-François; Vara Ouk; Segeral, Olivier // Journal of AIDS & Clinical Research;2012, Vol. 3 Issue 6, Special section p1 

    Background: Little is known about HIV/Hepatitis C Virus (HCV) co-infection in resource-limited countries, although chronic HCV infection is one of the most relevant comorbidities in HIV population. The aim of this study was to determine the severity of liver disease in a cohort of HIV/HCV...

  • Prevalence of anaemia among HIV-infected patients in Benin City, Nigeria. OMOREGIE, R.; OMOKARO, E. U.; PALMER, O.; OGEFERE, H. O.; EGBEOBAUWAYE, A.; ADEGHE, J. E.; OSAKUE, S. I.; IHEMEJE, V. // Tanzania Journal of Health Research;Feb2009, Vol. 11 Issue 1, p1 

    The aim of this study was to use the World Health Organization (WHO) definition of anaemia to determine prevalence of anaemia among human immunodeficiency virus (HIV)-infected patients on the highly active antiretroviral therapy (HAART) and those that are HAART naive. Haemoglobin concentration...

  • Coccidioidomycosis in Patients with HIV-1 Infection in the Era of Potent Antiretroviral Therapy. Masannat, Fares Y.; Ampel, Neil M. // Clinical Infectious Diseases;1/1/2010, Vol. 50 Issue 1, p1 

    Background. Coccidioidomycosis is a common opportunistic infection in human immunodeficiency virus type 1 (HIV-1)-infected individuals living in regions where coccidioidomycosis is endemic. However, there have been no studies on its incidence or clinical expression during the era of potent...

  • Didanosine/nevirapine/zidovudine.  // Reactions Weekly;8/11/2007, Issue 1164, p13 

    The article describes the case of a woman who developed nodular regenerative hyperplasia during treatment with highly active antiretroviral therapy (HAART), including didanosine, nevirapine and zidovudine, for HIV infection. The patient, who had a history of liver fracture and had been diagnosed...

  • Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. Dahab, Mison; Charalambous, Salome; Karstaedt, Alan S.; Fielding, Katherine L.; Hamilton, Robin; La Grange, Lettie; Churchyard, Gavin J.; Grant, Alison D. // BMC Public Health;2010, Vol. 10 Issue 1, p430 

    Background: Many national antiretroviral therapy (ART) programmes encourage providers to identify and address baseline factors associated with poor treatment outcomes, including modifiable adherence-related behaviours, before initiating ART. However, evidence on such predictors is scarce, and...

  • NEW HIV RECOMMENDATIONS TO IMPROVE HEALTH, REDUCE INFECTIONS AND SAVE LIVES.  // Central European Journal of Public Health;2010, Vol. 18 Issue 2, p115 

    The article reports on HIV recommendations that will be released by the World Health Organization (WHO) in 2010. The recommendations will include the use of antiretroviral drugs (ARVs) for the reduction of HIV transmission between mother and child, the type of ARVs that will be delivered, and...

  • Adverse Effects of Highly Active Anti-Retroviral Therapy (HAART). Hima Bindu, A.; Naga Anusha, P. // Journal of Antivirals & Antiretrovirals;2011, Vol. 3 Issue 4, p60 

    HIV/AIDS remains the greatest public health concern in the world. Nowadays HIV-AIDS is considered as a chronic disease due to the advent of highly active antiretroviral therapy. This therapy has significantly improved the status of the infected population, making HIV a manageable illness....

  • Socioeconomic Status and Survival of People with Human Immunodeficiency Virus Infection before and after the Introduction of Highly Active Antiretroviral Therapy: A Systematic Literature Review. Pavlova-McCalla, Elena; Trepka, Mary Jo; Ramirez, Gilbert; Niyonsenga, Theophile // Journal of AIDS & Clinical Research;2012, Vol. 3 Issue 6, Special section p1 

    Background: Human immunodeficiency virus/acquired immunodeficiency disease syndrome-associated mortality contributes considerably to overall mortality rates among adults in the United States. The purpose of this review is to systematically examine conceptual approaches that have been used to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics